Tsai Miaw-Sheue, Bogart Daphne F, Li Patricia, Mehmi Inderjit, Lupu Ruth
Ernest Orlando Lawrence Berkeley National Laboratory, University of California, One Cyclotron Road, Berkeley, CA 94720, USA.
Oncogene. 2002 Jan 31;21(6):964-73. doi: 10.1038/sj.onc.1205131.
We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.
我们已经表明,血管生成调节因子Cyr61在侵袭性和转移性人乳腺癌细胞及肿瘤活检组织中过表达。我们进一步证明,Cyr61在体内可促进乳腺癌细胞获得雌激素非依赖性和抗雌激素抗性。此外,我们还证明,Cyr61在体内可诱导肿瘤形成和肿瘤血管生成,这些事件是通过丝裂原活化蛋白激酶(MAPK)和Akt信号通路的激活介导的。在此,我们研究Cyr61在雌激素受体(ER)阳性和ER阴性乳腺癌细胞中的表达是如何被调控的。我们证明,在ER阳性乳腺癌细胞中,雌激素和抗雌激素可诱导Cyr61 mRNA和蛋白表达。我们表明,一种不稳定蛋白以及一种负调节因子可能参与雌激素依赖性乳腺癌细胞中Cyr61的表达。我们发现的乳腺癌细胞中Cyr61表达的其他重要调节因子是佛波酯TPA、维生素D和视黄酸。TPA对ER阳性MCF-7细胞中Cyr61表达具有正向调节作用。维生素D对Cyr61基因表达有短暂的刺激作用。最后,视黄酸对Cyr61表达有负面影响,并下调其在MCF-7细胞中的表达。有趣的是,在不表达ER且Cyr61表达水平高的侵袭性乳腺癌细胞(如MDA-MB-231细胞)中,这些作用大多未观察到。我们的结果与我们的认知一致,即Cyr61促进肿瘤生长,且肿瘤促进剂对表达低水平Cyr61的细胞(如ER阳性乳腺癌细胞)有正向影响;然而,这些试剂对表达高水平Cyr61的细胞没有显著影响。我们的研究结果表明Cyr61表达增加与乳腺癌细胞的侵袭性表型之间存在关联。